Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities

The Durham facility is part of an $800 million investment over the past six years to build three scalable, state-of-the-art gene therapy manufacturing facilities to support Pfizer’s continued investment in gene therapy research, development, and manufacturing.

Related Keywords

New York ,United States ,North Carolina ,Andover ,Hampshire ,United Kingdom ,Missouri ,Pearl River ,Massachusetts ,Colorado ,California ,Boulder ,Cambridge ,Cambridgeshire ,Chapel Hill ,La Jolla ,Connecticut ,Paul Mensah ,Linkedin ,Pfizer Biotherapeutics Pharmaceutical Sciences Group ,Twitter ,Biotherapeutics Pharmaceutical Sciences At Pfizer ,Pfizer ,Exchange Commission ,Pfizer Inc ,Facebook ,Vice President ,Breakthroughs That Change Patient ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,Bioethics ,Manufacturing ,Molecular Biology ,Nasdaq ,Pharmaceuticals ,Rare Diseases ,Therapy ,Us Securities And Exchange Commission ,Applied Genetics ,Articles ,Branches Of Biology ,Gene Delivery ,Gene Therapy ,Medical Genetics ,Vectors In Gene Therapy ,